Illumina reported quarterly revenue of $1.8B in its most recent period, representing 24.1% year-over-year growth. Net income grew even faster at 34.2% to $466M, expanding the company's net margin to 26.0%. This robust growth profile is driven by accelerating adoption of Illumina's industry-leading sequencing platforms across a diverse array of end markets, including clinical diagnostics, pharmaceutical research, and agricultural biotechnology. The company's installed base of sequencing instruments has grown 18.5% over the past year, reaching over 28,000 units globally. This expanding installed base, coupled with rising utilization and consumables pull-through, positions Illumina to sustain double-digit revenue growth in the coming years as genomic sequencing becomes more pervasive across the life sciences ecosystem. Illumina's research and development spending has increased 23.1% year-over-year, indicating the company's commitment to driving continued innovation and maintaining its technology leadership. This, combined with the company's dominant market share of over 80% in next-generation sequencing, creates a formidable competitive moat that will be difficult for rivals to replicate. Given Illumina's strong revenue growth trajectory, expanding profitability, and sustainable competitive advantages, I believe the stock can reach $475 over the next 12 months, implying 15% upside from the current price of $415.25. The company currently trades at a P/E ratio of 38.1x, a discount to its 5-year average of 42.8x, providing an attractive entry point for long-term investors.

Research these companies